<DOC>
	<DOC>NCT00950989</DOC>
	<brief_summary>Randomized, double-blind, placebo-controlled study in subjects with RA who have an inadequate response to methotrexate.</brief_summary>
	<brief_title>AMG 827 in Rheumatoid Arthritis Subjects With Inadequate Response to Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Active RA for least 6 months Current RA defined as ≥ 6 swollen joints (out of 66 joints examined) and ≥ 8 tender/painful joints (out of 68 joints examined) at screening and baseline (swollen and tender/painful joint count must not include distal interphalangeal joints) and at least 1 of the following at screening: Erythrocyte sedimentation rate ≥ 28 mm or Creactive protein &gt; 15 mg/L At least 1 of the following at screening: Rheumatoid factor positive or Anticyclic citrullinated peptide antibody positive Currently taking methotrexate for ≥ 12 weeks and on a stable dose of methotrexate at 15 to 25 mg weekly for ≥ 4 weeks at day 1. Prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening Class IV RA Felty's syndrome Presence of serious infection Significant concurrent medical conditions Pregnant or breast feeding Significant Laboratory abnormalities Any DMARD other than methotrexate within 28 days Leflunomide or live vaccines within 3 months Previous use of any experimental or commercially available biologic DMARD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Arthritis, Rheumatoid</keyword>
	<keyword>Rheumatic Diseases</keyword>
</DOC>